- Home
- MAX vs AUTL Comparison
MAX vs AUTL Comparison
Compare MAX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- AUTL
- Stock Information
- Founded
- MAX 2014
- AUTL 2014
- Country
- MAX United States
- AUTL United Kingdom
- Employees
- MAX N/A
- AUTL N/A
- Industry
- MAX Industrial Machinery/Components
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MAX Industrials
- AUTL Health Care
- Exchange
- MAX Nasdaq
- AUTL Nasdaq
- Market Cap
- MAX 613.7M
- AUTL 590.8M
- IPO Year
- MAX 2020
- AUTL 2018
- Fundamental
- Price
- MAX $11.24
- AUTL $2.19
- Analyst Decision
- MAX Buy
- AUTL Strong Buy
- Analyst Count
- MAX 8
- AUTL 3
- Target Price
- MAX $22.00
- AUTL $10.20
- AVG Volume (30 Days)
- MAX 460.9K
- AUTL 1.4M
- Earning Date
- MAX 02-18-2025
- AUTL 03-13-2025
- Dividend Yield
- MAX N/A
- AUTL N/A
- EPS Growth
- MAX N/A
- AUTL N/A
- EPS
- MAX 0.19
- AUTL N/A
- Revenue
- MAX $681,230,000.00
- AUTL $10,091,000.00
- Revenue This Year
- MAX $124.41
- AUTL $851.83
- Revenue Next Year
- MAX $31.11
- AUTL $264.18
- P/E Ratio
- MAX $59.54
- AUTL N/A
- Revenue Growth
- MAX 72.47
- AUTL 82.71
- 52 Week Low
- MAX $10.21
- AUTL $2.07
- 52 Week High
- MAX $25.78
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- MAX 46.70
- AUTL 37.25
- Support Level
- MAX $11.02
- AUTL $2.18
- Resistance Level
- MAX $11.45
- AUTL $2.38
- Average True Range (ATR)
- MAX 0.45
- AUTL 0.16
- MACD
- MAX 0.08
- AUTL 0.01
- Stochastic Oscillator
- MAX 59.63
- AUTL 3.17
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.